DAAOI-P

DAAOI-P is presumed to be a small molecule inhibitor of d-amino acid oxidase (DAAO), an enzyme that degrades d-amino acids such as d-serine in the brain. Inhibition of DAAO increases levels of d-serine, which acts as a co-agonist at the NMDA receptor, potentially enhancing NMDA receptor function. This mechanism is relevant for neuropsychiatric conditions like schizophrenia, where NMDA receptor hypofunction has been implicated. While there are references to related compounds such as DAAOI-2 being developed for treatment-resistant schizophrenia and acting both as a DAAO inhibitor and an NMDA receptor agonist, no direct information about "DAAOI-P" was found in the provided sources. Based on naming conventions and context from similar compounds (e.g., DAAOI-2), it is likely that DAAOI-P shares this mechanism and therapeutic rationale[2][9].

Other names

sodium benzoate